Exploration of the urocontrin A scaffold yields new urotensinergic system allosteric modulator and competitive antagonists
Biochemical Pharmacology · 2023
DOI: 10.1016/j.bcp.2023.115485 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Etienne Billard und 2 weiteren Autor:innen. Beteiligte Einrichtung: INRS - Centre Armand-Frappier Santé Biotechnologie, Groupe de Recherche en Ingénierie des Peptides et en Pharmacothérapie (GRIPP), Université du Québ…. Hauptthemen laut MEDLINE: Urotensins, Peptide Hormones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: CIHR, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
The urotensinergic system, involved in the development and/or progression of numerous pathological conditions, is composed of one G protein-coupled receptor (UT) and two endogenous ligands known as urotensin II (UII) and urotensin II-related peptide (URP). These two structurally related hormones, which exert common and divergent effects, are thought to play specific biological roles. In recent years, we have characterized an analog termed urocontrin A (UCA), i.e. [Pep4]URP, which is capable of discriminating the effects of UII from URP. Such an action could allow the delineation of the respective functions of these two endogenous ligands. In an effort to define the molecular determinants involved in this behavior and to improve the pharmacological profile of UCA, we introduced modifications from urantide, considered for some time as a lead compound for the development of UT antagonists, into UCA and assessed the binding, contractile activity and G protein signaling of these newly developed compounds. Our results show that UCA and its derivatives exert probe-dependent effects on UT antagonism, and we have further identified [Pen2, Pep4]URP as a Gq biased ligand with an insurmountable antagonism in our aortic ring contraction assay.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INRS - Centre Armand-Frappier Santé Biotechnologie, Groupe de Recherche en Ingénierie des Peptides et en Pharmacothérapie (GRIPP), Université du Québec, Ville de Laval, Québec H7V 1B7, Canada; Department of Pharmacology…
- Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec H3A 1A3, Canada.
- INRS - Centre Armand-Frappier Santé Biotechnologie, Groupe de Recherche en Ingénierie des Peptides et en Pharmacothérapie (GRIPP), Université du Québec, Ville de Laval, Québec H7V 1B7, Canada.
Förderung
- CIHR
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- Mitacs
Zitieren
APA
Billard, E., Hébert, T. E., & Chatenet, D. (2023). Exploration of the urocontrin A scaffold yields new urotensinergic system allosteric modulator and competitive antagonists. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115485
Vancouver
Billard E, Hébert TE, Chatenet D. Exploration of the urocontrin A scaffold yields new urotensinergic system allosteric modulator and competitive antagonists. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115485
BibTeX
@article{Billard2023,
author = {Billard, Etienne and Hébert, Terence E and Chatenet, David},
title = {Exploration of the urocontrin A scaffold yields new urotensinergic system allosteric modulator and competitive antagonists},
journal = {Biochemical Pharmacology},
year = {2023},
doi = {10.1016/j.bcp.2023.115485}
}
EUVIMED